SEC Form 4 · accession 0001144204-18-064511
Fortress Biotech, Inc. · FBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Avgerinos
Officer — SVP, BIOLOGICS OPERATIONS
Period of report
Dec 11, 2018
Accepted (ET)
Dec 13, 2018 · 6:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001429260
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.001F1,F2 | Dec 11, 2018 | S | 97,325 | $1.05 | D | 255,170 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person had no discretion with respect to such sale, which was conducted automatically by the Issuer's administrator in order to satisfy the reporting person's tax withholding obligations.
- F2Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the sale transactions on December 11, 2018, was $1.03 to $1.10. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price.